edison tv
Investment Companies
“Edison is the go-to for a new investor to get full understanding of the investment case and business. Edison’s distribution reaches investors that we want to connect with directly.”
Associated equity: Ultimovacs
Edison Investment Research is terminating coverage on Ultimovacs (ULTI). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.
Ultimovacs — 7 videos in collection
Ultimovacs is developing novel immunotherapies against cancer. The lead product candidate, UV1, is a peptide-based vaccine against the universal cancer antigen telomerase (human telomerase reverse transcriptase), which is expressed in c 85% of all cancer types. UV1 therefore has broad potential in a variety of different settings and combinations.
In this video, CEO Carlos de Sousa and CMO Jens Bjørheim provide an update on the data shared from the legacy Phase I trial, including survival, responses and biomarkers.
Get access to the very latest content matched to your personal investment style.